The positive Phase 1b/2a symptom data de-risks the EP-104GI program ahead of the pivotal Phase 2b interim readout in Q4 2026. Traders should monitor for any additional data disclosures and the initiation of the Phase 2b interim analysis, which will be the next major catalyst.
Price Chart
Executive Summary
Eupraxia Pharmaceuticals reported positive symptom response data from its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in eosinophilic esophagitis (EoE). New data showed a reduction in patients experiencing moderate to severe odynophagia (painful swallowing) from 62% at baseline to 25% at 24-52 weeks, and a reduction in moderate to severe dysphagia (difficulty swallowing) from 77% at baseline to 25% at 24-52 weeks. The company anticipates a key Phase 2b placebo-controlled interim readout in Q4 2026, making this a notable but early-stage catalyst update for a pre-revenue biotech.
Key Facts
- New analysis of Phase 1b/2a RESOLVE trial data shows reduction in moderate to severe odynophagia from 62% at baseline to 25% at 24-52 weeks post-treatment.
- Moderate to severe dysphagia reduced from 77% at baseline to 25% at 24 and 52 weeks post-treatment.
- No patients reported severe odynophagia or severe dysphagia at the 24 and 52 week timepoints.
- EP-104GI continues to be well tolerated with no treatment-emergent or procedure-related Serious Adverse Events (SAEs) reported in over 130 patients.
- Phase 2b placebo-controlled interim data from the RESOLVE trial is expected in Q4 2026.
Financial Impact
No financial data provided; pre-revenue clinical-stage company. The catalyst is the positive clinical data readout and upcoming Phase 2b interim data.
Risk Factors
- Phase 2b placebo-controlled trial may fail to replicate these open-label results.
- Company has no approved products or revenue, requiring future financing to fund operations and trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005479 |
| Document: f6k_081326.htm | 0001171843-26-005479 |
| Document: 0001171843-26-005479-index-headers.html | 0001171843-26-005479 |
| Document: 0001171843-26-005479-index.html | 0001171843-26-005479 |
| Document: 0001171843-26-005479.txt | 0001171843-26-005479 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 6-K | $7.59 | awaiting T+5 | — | $7.08 (−6.72%) |
Oct 15, 2026 12d ago | 6-K | $6.77 $7.59 | ▲ +12.11% | ▲ +13.13% | $7.08 (+4.58%) |
Oct 9, 2026 18d ago | 6-K | $7.46 $6.62 | ▼ −11.26% | ▼ −9.29% | $7.08 (−5.09%) |
Sep 30, 2026 27d ago | 6-K | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Sep 30, 2026 27d ago | Press Release | $9.10 $7.78 | ▼ −14.51% | ▼ −16.42% | $7.08 (−22.20%) |
Aug 25, 2026 9w ago | EFFECT | $7.42 $6.34 | ▲ +14.56% | ▲ +14.02% | $7.08 (+4.58%) |
Aug 13, 2026 10w ago | 6-K | $6.67 $6.76 | ▲ +1.35% | ▲ +3.31% | $7.08 (+6.15%) |
Aug 11, 2026 11w ago | Press Release | $6.48 $7.01 | ▲ +8.18% | ▲ +8.62% | $7.08 (+9.26%) |
Jul 15, 2026 14w ago | 6-K | $6.52 $6.42 | ▼ −1.53% | ▼ −0.55% | $7.08 (+8.59%) |
Jun 19, 2026 18w ago | Press Release | $6.64 $6.60 | ▼ −0.60% | ▲ +1.47% | $7.08 (+6.63%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers